نتایج جستجو برای: her2 amplification

تعداد نتایج: 71537  

Journal: :Human pathology 2017
Yoshifumi Shimada Ryoma Yagi Hitoshi Kameyama Masayuki Nagahashi Hiroshi Ichikawa Yosuke Tajima Takuma Okamura Mae Nakano Masato Nakano Yo Sato Takeaki Matsuzawa Jun Sakata Takashi Kobayashi Hitoshi Nogami Satoshi Maruyama Yasumasa Takii Takashi Kawasaki Kei-Ichi Homma Hiroshi Izutsu Keisuke Kodama Jennifer E Ring Alexei Protopopov Stephen Lyle Shujiro Okuda Kohei Akazawa Toshifumi Wakai

HER2-targeted therapy is considered effective for KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (CRC). In general, HER2 status is determined by the use of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Comprehensive genomic sequencing (CGS) enables the detection of gene mutations and copy number alterations including KRAS mutation and HER2 amp...

2015
Tao Wang Yutaka Amemiya Pauline Henry Arun Seth Wedad Hanna Eugene T. Hsieh

Therapy with trastuzumab confers a survival benefit in HER2 positive advanced gastric and gastroesophageal adenocarcinoma. HER2 status is evaluated by immunohistochemistry (IHC) and in situ hybridization (ISH). An ISH ratio of HER2 to centromere 17 (CEP17) ≥2.0 is considered amplified. This assumes that CEP17 reflects chromosomal copy number. Cases where CEP17 exceeds 3 are classified as polyso...

2016
Qian-Qian Xu Bo Pan Chang-Jun Wang Yi-Dong Zhou Feng Mao Yan Lin Jing-Hong Guan Song-Jie Shen Xiao-Hui Zhang Ya-Li Xu Ying Zhong Xue-Jing Wang Yan-Na Zhang Qiang Sun

BACKGROUND Trastuzumab-based therapy is a standard, targeted treatment for HER2-positive breast cancer in the adjuvant setting. However, patients do not benefit equally from it and the association between HER2 amplification level and patients' survival remains controversial. A systematic review and meta-analysis was conducted by incorporating all available evidence to evaluate the association b...

2006
KAZUHIRO SUMIYOSHI YURO SHIBAYAMA TAKEHIRO NOHARA MITSUHIKO IWAMOTO TOSHIHIRO KOBAYASHI HARUTO NISHIMURA RYOJI YOSHINAKA TOMOAKI HARADA NOBUHIKO TANIGAWA

Overexpression of HER2 protein and HER2 gene amplification in breast cancer are prognostic factors for the response to specific medical treatments such as trastuzumab, endocrine therapy, and chemotherapy. Whereas HER2 expression and gene amplification are generally examined in tissue sections, we investigated whether specimens from fine needle aspiration cytology (FNAC) are adequate for these a...

2014
Zsuzsanna Varga Raymond R. Tubbs Holger Moch

INTRODUCTION HER2 status assessment became a mandatory test assay in breast cancer, giving prognostic and predictive information including eligibility for adjuvant anti-HER2 therapy. Precise and reliable assessment of HER2 status is therefore of utmost importance. In this study we analyzed breast cancer samples by a novel technology for concomitant detection of the HER2 protein and gene copy nu...

Journal: :Archives of pathology & laboratory medicine 2009
Gail H Vance Todd S Barry Kenneth J Bloom Patrick L Fitzgibbons David G Hicks Robert B Jenkins Diane L Persons Raymond R Tubbs M Elizabeth H Hammond

CONTEXT Intratumoral heterogeneity of HER2 gene amplification has been well documented and represents subclonal diversity within the tumor. The reported incidence of intratumor HER2 amplification genetic heterogeneity ranges in the literature from approximately 5% to 30%. The presence of HER2 genetic heterogeneity may increase subjectivity in HER2 interpretation by the pathologist. OBJECTIVES...

Journal: :Archives of otolaryngology--head & neck surgery 2007
Giorgio Cornolti Marco Ungari Maria Laura Morassi Fabio Facchetti Elisa Rossi Davide Lombardi Piero Nicolai

OBJECTIVES To detect amplification of the HER2/neu gene by means of fluorescence in situ hybridization (FISH) in a series of 13 salivary duct carcinomas (SDCs) and to compare the results with immunohistochemical (IHC) assessment of HER2/neu protein expression. DESIGN Retrospective analysis. SETTING Department of Pathology, University of Brescia. PATIENTS We studied 13 cases of SDC diagnos...

2009
N. Todorović-Raković Z. Nešković-Konstantinović D. Nikolić-Vukosavljević

The aim of this study was to determine the relationship between amplification of HER2 (Human epidermal growth factor receptor 2) and Topo2a (topoisomerase 2a) and their influence on prognosis in metastatic breast cancer (MBC) patients. Amplification of both HER2 and Topo2a genes was determined by chromogenic in situ hybridization (CISH) in primary tumor tissue of 71 MBC patients. Starting point...

2014
HUIYONG JIANG XIAOYAN BAI FANJUN MENG CHENG ZHANG XUEFENG ZHANG

Human epidermal growth factor receptor 2 (HER2) amplification and overexpression are associated with poor prognosis and resistance to cytotoxic drugs in patients with breast cancer. Increases in the number of HER2 gene copies have been shown to be associated with chromosome 17 polysomy. The use of whole, intact nuclei for fluorescence in situ hybridization (FISH) assay improves the accuracy of ...

Journal: :Molecular cancer therapeutics 2010
Junko Tanizaki Isamu Okamoto Ken Takezawa Sayaka Tsukioka Junji Uchida Mamoru Kiniwa Masahiro Fukuoka Kazuhiko Nakagawa

Amplification of human epidermal growth factor receptor 2 (HER2) has been detected in 20% to 30% of gastric cancers and is associated with a poor outcome. Combination therapies with HER2-targeting agents and cytotoxic agents are considered a potential therapeutic option for gastric cancer with HER2 amplification. We have now investigated the effects of combination treatment with the oral fluoro...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید